Shin Takenaka1, Walter Ventura2, Anna Freni Sterrantino3, Akihiro Kawashima4, Keiko Koide4, Kyoko Hori4, Antonio Farina5, Akihiko Sekizawa4. 1. Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan shin-take@med.showa-u.ac.jp. 2. Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan Fetal Medicine Unit, Instituto Nacional Materno Perinatal, Lima, Peru. 3. Department of Statistical Sciences, University of Bologna, Bologna, Italy. 4. Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan. 5. Department of Medicine and Surgery (DIMEC), Division of Prenatal Medicine, University of Bologna, Bologna, Italy.
Abstract
OBJECTIVE: To predict the occurrence of fetal growth restriction (FGR) by analyzing messenger RNA (mRNA) expression levels of vascular endothelial growth factor receptor 1 (fms-like tyrosine kinase 1 [Flt-1]) in maternal blood. STUDY DESIGN: Eleven women with FGR were matched with 88 controls. Plasma samples were obtained during each trimester. The Flt-1 mRNA expression levels were compared between groups. Predicted probabilities were calculated, and sensitivity-specificity (receiver-operating characteristic [ROC]) curves were assessed based on regression models for each trimester measurement and possible combinations of measurements. RESULTS: The mRNA levels of the FGR group during all trimesters were significantly higher than those of the control group. The ROC curve of combined first and second trimester data yielded a detection rate of 60% at a 10% false-positive rate, with an area under curve of 0.79. CONCLUSION: The Flt-1 mRNA expression in maternal blood can be used as a marker to predict the development of FGR, long before a clinical diagnosis is made.
OBJECTIVE: To predict the occurrence of fetal growth restriction (FGR) by analyzing messenger RNA (mRNA) expression levels of vascular endothelial growth factor receptor 1 (fms-like tyrosine kinase 1 [Flt-1]) in maternal blood. STUDY DESIGN: Eleven women with FGR were matched with 88 controls. Plasma samples were obtained during each trimester. The Flt-1 mRNA expression levels were compared between groups. Predicted probabilities were calculated, and sensitivity-specificity (receiver-operating characteristic [ROC]) curves were assessed based on regression models for each trimester measurement and possible combinations of measurements. RESULTS: The mRNA levels of the FGR group during all trimesters were significantly higher than those of the control group. The ROC curve of combined first and second trimester data yielded a detection rate of 60% at a 10% false-positive rate, with an area under curve of 0.79. CONCLUSION: The Flt-1 mRNA expression in maternal blood can be used as a marker to predict the development of FGR, long before a clinical diagnosis is made.
Authors: Winnie W I Pang; Michelle H Y Tsui; Daljit Sahota; Tak Y Leung; Tze K Lau; Y M Dennis Lo; Rossa W K Chiu Journal: Prenat Diagn Date: 2009-05 Impact factor: 3.050
Authors: Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808